3289-76-7Relevant articles and documents
An Isoquinolinium Dual Inhibitor of Cholinesterases and Amyloid β Aggregation Mitigates Neuropathological Changes in a Triple-Transgenic Mouse Model of Alzheimer's Disease
Ju, Yaojun,Chakravarty, Harapriya,Tam, Kin Yip
, p. 3346 - 3357 (2020)
Alzheimer's disease (AD) is a complex neurodegenerative disorder affecting millions of people worldwide. The underlying pathologic mechanisms of AD are unclear. Over the decades, the development of single target agent did not lead to any successful treatm
Discovery of a Potent Botulinum Neurotoxin A Inhibitor ZM299 with Effective Protections in Botulism Mice
Gao, Jie,He, Zhili,Hong, Zhanying,Li, Tao,Luo, Deyan,Miao, Zhenyuan,Ning, Nianzhi,Wang, Hui,Wang, Jianxin,Wu, Yuelin,Xv, Xiguo,Zhang, Wannian,Zhang, Yanming,Zhuang, Chunlin
, p. 357 - 364 (2021/12/24)
Botulinum neurotoxins serotype A (BoNT/A) is the deadliest toxins known to humans and the "Category A" agent for bioterrorism. Over the past 20 years, significant efforts have been put forth to develop effective inhibitors of BoNT/A. Unfortunately, few id
CXCR6 INHIBITORS AND METHODS OF USE
-
Paragraph 0292, (2021/01/29)
Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthe